Association Between Triglyceride-glucose Index and Clinical Outcomes Among Patients with Chronic Kidney Disease: a Meta-analysis

Overview

Journal BMC Nephrol

Publisher Biomed Central

Date 2025 Feb 6

PMID 39915738

Authors

Jinli Tuo

Zhong Li

Linshen Xie

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify the relationship of triglyceride-glucose (TyG) index with clinical outcomes in chronic kidney disease (CKD) patients based on current available evidence.

Methods: PubMed, EMBASE, Web of Science and CNKI databases were searched up to August 31, 2024. Primary outcome was the all-cause mortality. Secondary outcomes included the coronary artery disease (CAD) mortality, CKD progression, risk of severe coronary artery stenosis (SCAS), major adverse cardiovascular event (MACE), coronary artery calcification (CAC) progression, end-stage renal disease (ESRD), and nonalcoholic fatty liver disease (NAFLD). The hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were combined to assess the predictive role of TyG index for above clinical outcomes among CKD patients. All statistical analysis was performed by STATA 15.0 version.

Results: Twelve studies with 26,530 cases were included. Pooled results indicated that elevated TyG index was significantly related to increased risk for all-cause mortality (HR = 1.22, 95% CI: 1.13-1.31, P<0.001). Besides, high TyG index was also associated with the CAD mortality (HR = 1.19, 95% CI: 1.04-1.36, P = 0.011), occurrence of CKD progression (HR = 1.52, 95% CI: 1.36-1.70, P<0.001), SCAS (OR = 1.79, 95% CI: 1.13-2.83, P = 0.013), MACE (OR = 1.68, 95% CI: 1.11-2.54, P = 0.014), CAC progression (OR = 1.55, 95% CI: 1.06-1.76, P = 0.02), CAD (OR = 2.865, 95% CI: 1.681-4.885, P<0.001), ESRD (OR = 1.49, 95% CI: 1.12-1.99, P = 0.006) and NAFLD (OR = 4.903, 95% CI: 3.046-7.893, P<0.001).

Conclusion: High TyG index predicts poor clinical outcomes and might serve as a novel prognostic indicator among CKD patients. However, more studies are still needed to verify above findings.

References

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Colladant M, Chabannes M, Crepin T, Bamoulid J, Courivaud C, Ducloux D . Triglyceride-Glucose Index and Cardiovascular Events in Kidney Transplant Recipients. Kidney Int Rep. 2023; 8(11):2307-2314. PMC: 10658270. DOI: 10.1016/j.ekir.2023.08.021. View

Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P . Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022; 21(1):124. PMC: 9250255. DOI: 10.1186/s12933-022-01546-0. View

Bhandari S, Mehta S, Khwaja A, Cleland J, Ives N, Brettell E . Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022; 387(22):2021-2032. DOI: 10.1056/NEJMoa2210639. View

Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B . Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2018; 34(6):975-991. DOI: 10.1007/s00467-018-4005-4. View

Webster A, Nagler E, Morton R, Masson P . Chronic Kidney Disease. Lancet. 2016; 389(10075):1238-1252. DOI: 10.1016/S0140-6736(16)32064-5. View

Lee B, Ahmed F, Hamm L, Teran F, Chen C, Liu Y . Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015; 16:77. PMC: 4449580. DOI: 10.1186/s12882-015-0068-7. View

Wang Y, Li J, Chang S, Dong Y, Che G . Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases. J Thorac Oncol. 2021; 16(11):1893-1908. DOI: 10.1016/j.jtho.2021.07.001. View

Ko Y, Kim H, Park J, Han S, Kang S, Sung S . Triglyceride-glucose index is an independent predictor of coronary artery calcification progression in patients with chronic kidney disease. Kidney Res Clin Pract. 2024; 43(3):381-390. PMC: 11181041. DOI: 10.23876/j.krcp.23.264. View

10.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B . Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888):260-72. DOI: 10.1016/S0140-6736(13)60687-X. View

11.

Gao Y, Chen W, Deng Z, Shang Z, Wang Y . Association between triglyceride-glucose index and risk of end-stage renal disease in patients with type 2 diabetes mellitus and chronic kidney disease. Front Endocrinol (Lausanne). 2023; 14:1150980. PMC: 10157287. DOI: 10.3389/fendo.2023.1150980. View

12.

Chen Y, Li S, Yang K, Wu B, Xie D, Peng C . Triglyceride-glucose index and prognosis in individuals afflicted with heart failure and chronic kidney disease. ESC Heart Fail. 2024; 11(5):3120-3132. PMC: 11424337. DOI: 10.1002/ehf2.14898. View

13.

Spoto B, Pisano A, Zoccali C . Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016; 311(6):F1087-F1108. DOI: 10.1152/ajprenal.00340.2016. View

14.

Reum Choe A, Ryu D, Kim H, Lee H, Lim J, Kim J . Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol. 2020; 21(1):50. PMC: 7027038. DOI: 10.1186/s12882-020-01718-8. View

15.

Qin Y, Xuan L, Deng Y, Wang F, Liu B, Wang S . Triglyceride-glucose index and mortality risk in individuals with or without chronic kidney disease: Insights from a national survey of United States adults, 1999-2018. Nutr Metab Cardiovasc Dis. 2024; 34(8):1994-2001. DOI: 10.1016/j.numecd.2024.04.003. View

16.

Liu D, Guan X, Chen R, Song C, Qiu S, Xu S . The clinical evaluation of the triglyceride-glucose index as a risk factor for coronary artery disease and severity of coronary artery stenosis in patients with chronic kidney disease. Ren Fail. 2024; 46(1):2320261. PMC: 10901187. DOI: 10.1080/0886022X.2024.2320261. View

17.

Kong A, Xu G, Brown N, So W, Ma R, Chan J . Diabetes and its comorbidities--where East meets West. Nat Rev Endocrinol. 2013; 9(9):537-47. DOI: 10.1038/nrendo.2013.102. View

18.

Yen F, Hwu C, Liu J, Wu Y, Chong K, Hsu C . Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease. Ann Intern Med. 2024; 177(6):693-700. DOI: 10.7326/M23-1874. View

19.

Low S, Pek S, Moh A, Ang K, Khoo J, Shao Y . Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes - mediation by pigment epithelium-derived factor. Diab Vasc Dis Res. 2022; 19(4):14791641221113784. PMC: 9364218. DOI: 10.1177/14791641221113784. View

20.

Yang Y, Huang X, Wang Y, Leng L, Xu J, Feng L . The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023; 22(1):2. PMC: 9825038. DOI: 10.1186/s12933-022-01732-0. View